Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10245372 | 0.80 | TAAR1 (0.48) | HTTGAAALDH1A1LMNAMAPT | |
| SCHEMBL28885120 | 0.79 | POLB (0.47) | HTTGAAKMT2AMEN1POLB | |
| SCHEMBL178423 | 0.76 | — | — | |
| SCHEMBL3159042 | 0.75 | LMNA (0.68) | KMT2AMEN1POLBALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL6121921 | 0.74 | — | — | |
| SCHEMBL9427413 | 0.73 | KMT2A (0.43) | HTTKMT2AMEN1POLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL6122085 | 0.73 | KMT2A (0.69) | HTTKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL13123453 | 0.73 | — | — | |
| SCHEMBL2719543 | 0.72 | — | — | |
| SCHEMBL1709286 | 0.72 | POLB (0.62) | HTTGAAKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20200039961-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-06 | — | — | US | disclosed |
| US-9914740-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-13 | — | — | US | disclosed |
| US-9914740-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-13 | — | — | US | disclosed |
| US-9527828-B2 | Method for expanding hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-12-27 | — | — | US | disclosed |
| US-9486422-B2 | Small molecule inhibitors of Mcl-1 and the uses of thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| US-9006243-B2 | HIV inhibiting 6-substituted pyrimidines | JANSSEN R&D IRELAND (IE) | 2015-04-14 | — | — | US | disclosed |
| US-9006243-B2 | HIV inhibiting 6-substituted pyrimidines | JANSSEN R&D IRELAND (IE) | 2015-04-14 | — | — | US | disclosed |
| US-8865708-B2 | Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-10-21 | — | — | US | disclosed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080306076-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-7326703-B2 | (1,10B-Dihydro-2-(aminocarbonyl-phenyl)-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors | TIBOTEC PHARMACEUTICALS LTD (IL) | 2008-02-05 | — | — | US | disclosed |
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | SB PHARMCO PUERTO RICO INC. AND NEUROCRINE BIOSCIENCES, INC., A CORPORATION | 2007-12-20 | — | — | US | disclosed |
| US-20070248624-A1 | (1,10B-Dihydro-2-(Aminocarbonyl-Phenyl)-5h-Pyrazolo[1,5-C][1,3]Benzoxazin-5-Yl)Phenyl Methanone Derivatives as Hiv Viral Replication Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2007-10-25 | — | — | US | disclosed |
| US-20070248624-A1 | (1,10B-Dihydro-2-(Aminocarbonyl-Phenyl)-5h-Pyrazolo[1,5-C][1,3]Benzoxazin-5-Yl)Phenyl Methanone Derivatives as Hiv Viral Replication Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2007-10-25 | — | — | US | disclosed |
| US-4806562-A | Substituted thieno[2,3-b]thiophene-2-sulfonamides as antiglaucoma agents | MERCK & CO., INC. (US) | 1989-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | HTT 4140/4885GAA 4502/4885KMT2A 1131/4885 |
| US-20080306076-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | OR51E2, TAS2R50, TAS2R30 | HTT 4002/4885GAA 4767/4885KMT2A 4389/4885 |
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | CRHR1, CRHR2, CRH | HTT 891/4885GAA 1986/4885KMT2A 2996/4885 |
| US-20200039961-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | SHMT1, BHMT, EHMT2 | HTT 189/4885GAA 529/4885KMT2A 27/4885 |
| US-20070248624-A1 | (1,10B-Dihydro-2-(Aminocarbonyl-Phenyl)-5h-Pyrazolo[1,5-C][1,3]Benzoxazin-5-Yl)Phenyl Methanone Derivatives as Hiv Viral Replication Inhibitors | POLRMT, MAVS, DHX15 | HTT 3555/4885GAA 1809/4885KMT2A 2814/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | HTT 1041/4885GAA 2676/4885KMT2A 35/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | HTT 868/4885GAA 551/4885KMT2A 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.